FDA Ruling Boosts Trinity Biotech

Trinity Biotech ( TRIB ) shares soared after regulators issued a waiver for the company's HIV test, broadening its legal use.

Shares rose 37 cents, or 12.2%, to $3.39 in heavy trading. More than 1.5 million shares changed hands, six times the normal daily volume.

Trinity's Uni-Gold Recombigen HIV test, which gives results within 10 minutes, was approved by the Food and Drug Administration last December.

The product has been waived for use in detecting HIV-1 antibodies in venous whole blood samples. The company said the waiver means it can now be used by almost 200,000 test sites in the U.S., including physician's offices and clinics, in addition to its previously approved applicability in the hospital environment.

The test detects antibodies to HIV in human serum, plasma and whole blood.

More from Stocks

Video: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Stocks Trade Mixed, Energy Shares Fall on Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Drop in Oil Prices

Top U.S. Regulators May Be Sowing the Seeds of the Next Financial Crisis

Top U.S. Regulators May Be Sowing the Seeds of the Next Financial Crisis

Fiat Chrysler Recalls 4.8 Million Vehicles Over Cruise Control Issue

Fiat Chrysler Recalls 4.8 Million Vehicles Over Cruise Control Issue

One Thing to Consider Over Memorial Day Weekend: Are Stocks About to Collapse?

One Thing to Consider Over Memorial Day Weekend: Are Stocks About to Collapse?